IDEXX Laboratories Inc. (IDXX) delivered a solid earnings beat on Monday, but the market had other ideas. Shares dropped 5.57% to $633.10 even after the animal health company reported fourth-quarter results that exceeded analyst expectations and issued an optimistic fiscal 2026 forecast.

The company posted fourth-quarter earnings of $3.08 per share, up 18% year over year and beating the consensus estimate of $2.94. Revenue came in at $1.091 billion, topping the $1.073 billion consensus with 14% reported growth and 12% organic growth.

So what happened? Sometimes beating expectations isn't enough, especially when your stock is already trading near all-time highs.

Pet Diagnostics Power the Quarter

The Companion Animal Group delivered the heavy lifting with $998.5 million in revenue, up 14.7%. CAG Diagnostics recurring revenue climbed 12% on a reported basis and 10% organically, outpacing broader sector growth. The U.S. market benefited from increased diagnostic testing frequency, with early signs that an aging pet population is driving more visits and tests.

But the real story was in capital equipment. CAG Diagnostics instrument revenue hit $58.13 million, surging 76% as reported and 69% organically. That growth came from record quarterly instrument placements, including over 1,900 IDEXX inVue Dx units and nearly 1,400 new and competitive Catalyst placements.

Water revenues grew 12% on a reported basis and 10% organically to $50.53 million, showing solid momentum in both U.S. and international markets. The Livestock, Poultry and Dairy segment posted $37.48 million in revenue, up 8% reported and 4% organically, driven by gains across North and Latin America.

Margins Expanding Despite Inflation

Gross profit increased 15% on a reported basis and 13% on a comparable basis to $658.1 million. Gross margin expanded to 60.3%, up 50 basis points as reported and 60 basis points on a comparable basis. Volume gains, reference laboratory productivity improvements, and net price realization helped offset inflationary pressures.

Operating margin hit 28.9% in the quarter, climbing 150 basis points year over year on a reported basis and 120 basis points on a comparable basis.

Looking Ahead to 2026

"We enter 2026 with an exciting innovation pipeline, expanding instrument and software installed bases, and strong momentum across our global business," said Jay Mazelsky, President and CEO, in a press release on Monday.

The company expects fiscal 2026 earnings of $14.29 to $14.80 per share compared to the consensus of $14.39. Revenue is projected at $4.632 billion to $4.720 billion versus the consensus of $4.658 billion, led by CAG Diagnostics recurring revenue growth of 8.6% to 10.6% on a reported basis and 8.0% to 10.0% organically.

The Analyst Take

"Despite end-market visit weakness, IDXX shares have been hovering near an all-time high in the midst of investor enthusiasm surrounding the company's new product cycle," William Blair wrote in an investor note on Monday.

Analyst Ryan S. Daniels added: "We believe Idexx's current innovation cycle should provide incremental confidence that the company has the levers it needs to meet expectations in this still-challenging environment."

In other words, the company executed well. But when you're already priced for perfection, sometimes even a beat isn't enough to keep the rally going.